您的购物车当前为空
别名 BCT-197
Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂,IC50值小于1 μM。


为众多的药物研发团队赋能,
让新药发现更简单!
Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂,IC50值小于1 μM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 176 | In stock | |
| 5 mg | ¥ 388 | In stock | |
| 10 mg | ¥ 645 | In stock | |
| 25 mg | ¥ 1,290 | In stock | |
| 50 mg | ¥ 1,980 | In stock | |
| 100 mg | ¥ 3,290 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 427 | In stock |
Acumapimod 相关产品
| 产品描述 | Acumapimod (BCT-197) is an orally active inhibitor of p38α MAPK (IC50 <1 μM). |
| 靶点活性 | p38α:<1 μM |
| 体内活性 | Acumapimod 在以6 mg/kg剂量给予的情况下,能够提高感染流感病毒H1N1 A/PR/8/34的小鼠模型的生存率,并减少支气管肺泡灌洗液(BALF)中的巨噬细胞数量[1]。 |
| 动物实验 | In vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with Acumapimod(BCT197) (a closely related p38 MAPK inhibitor with an IC50 value of<1?μM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24?h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically[1]. |
| 别名 | BCT-197 |
| 分子量 | 385.42 |
| 分子式 | C22H19N5O2 |
| CAS No. | 836683-15-9 |
| Smiles | Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1 |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 50 mg/mL (129.73 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.19 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容